Table 2.
irAE by organ system, type, and grade
| irAE by system | All patients (n = 186) | |
|---|---|---|
| Any grade, n (%) | Grade ≥3, n (%) | |
| No. of patients with ≥1 irAEa | 88 (47.3) | 27 (14.5) |
| Skin | ||
| Maculopapular rash | 29 (15.6) | 5 (2.7) |
| Hypopigmentation or vitiligo | 17 (9.1) | 0 (0) |
| Poliosis | 1 (0.5) | 0 (0) |
| Gastrointestinal | ||
| Diarrhea or enterocolitis | 27 (14.5) | 7 (3.8) |
| Hepatotoxicity | 12 (6.5) | 2 (1.1) |
| Pancreatitis | 11 (5.9) | 2 (1.1) |
| Endocrine | ||
| Hypothyroid or hyperthyroid | 21 (11.3) | 0 (0) |
| Hypophysitis or adrenal insufficiency | 6 (3.2) | 3 (1.6) |
| Hyperglycemia | 1 (0.5) | 1 (0.5) |
| Pulmonary | ||
| Pneumonitis | 11 (5.9) | 8 (4.3) |
| Rheumatological | ||
| Arthritis or arthralgia | 11 (5.9) | 3 (1.6) |
| Myositis | 3 (1.6) | 1 (0.5) |
| Renal | ||
| Acute kidney injury | 4 (2.2) | 1 (0.5) |
| Ocular | ||
| Uveitis | 2 (1.1) | 0 (0) |
a
Many patients had more than one irAE. Recurrence of the same irAE on subsequent cycles were not included.
Abbreviation: irAE, immune‐related adverse event.